Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Quest Diagnostics News

    126,60 € +0,36% +0,45 €
    10:13:15 Uhr Gettex aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 904533
    ISIN: US74834L1008
    US-Symbol: DGX
    Typ: Aktie
    Werbung
    Weiter aufwärts?
    Long Hebel 6,77
    ME92D5

    Quest Diagnostics News

    23.04.24 - PR Newswire
    Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
    Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 PR Newswire
    22.04.24 - PR Newswire
    Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
    Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease PR Newswire
    02.04.24 - PR Newswire
    Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
    Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-​Line Genetic Test for Developmental Delay PR Newswire
    26.03.24 - PR Newswire
    Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
    Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease PR Newswire
    19.03.24 - PR Newswire
    Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024
    Quest Diagnostics to Release First Quarter 2024 Financial Results on April 23, 2024 PR Newswire
    23.02.24 - PR Newswire
    Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference
    Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference PR Newswire
    21.02.24 - PR Newswire
    Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery
    Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery PR Newswire
    15.02.24 - PR Newswire
    Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
    Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection PR Newswire
    13.02.24 - PR Newswire
    Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
    Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery PR Newswire
    12.02.24 - PR Newswire
    First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com
    First PFAS "Forever Chemicals" Consumer-​Initiated Blood Test with Physician Consult Launches on questhealth.com PR Newswire
    08.02.24 - BNP Paribas
    Quest Diagnostics – Gedämpfte Gewinnperspektiven halten Aktie auf Talfahrt
    Der US-​Anbieter von diagnostischen Tests bekommt den Kollaps des Corona-​Geschäfts zu spüren. Vorstandschef Jim Davis konnte Investoren mit der Prognose nicht überzeugen.
    08.02.24 - BNP Paribas
    Quest Diagnostics – Gedämpfte Gewinnperspektiven halten Aktie auf Talfahrt
    Der US-​Anbieter von diagnostischen Tests bekommt den Kollaps des Corona-​Geschäfts zu spüren. Vorstandschef Jim Davis konnte Investoren mit der Prognose nicht überzeugen.
    01.02.24 - PR Newswire
    Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
    Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share PR ...
    31.01.24 - PR Newswire
    Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies"
    Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies" PR Newswire
    22.01.24 - PR Newswire
    Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma
    Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular ...
    17.01.24 - PR Newswire
    Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024
    Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024 PR Newswire
    17.01.24 - PR Newswire
    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health
    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health PR Newswire
    08.01.24 - PR Newswire
    Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System
    Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System PR Newswire
    08.01.24 - PR Newswire
    Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC
    Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC PR Newswire
    21.12.23 - PR Newswire
    Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference
    Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire

    Newssuche

    Videos

    newspaper
    08:40 Uhr +19,89%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »